UK-based biopharmaceutical firm Arecor has announced that its ultra-rapid acting insulin candidate, AT247, demonstrated encouraging pharmacokinetic and pharmacodynamic profiles in a Phase I clinical trial.

AT247 was compared to Novo Nordisk’s NovoRapid and Fiasp during the trial.

The ultra-rapid acting insulin formulation is intended for meal-time administration. It is designed to speed up insulin absorption for effective blood glucose levels management.

Arecor said that the therapy has the potential to boost postprandial glucose control, allow flexible insulin dosing and avoid hypo, as well as hyperglycaemia.

The double-blind, randomised, cross-over, three-period Phase I trial was conducted at The Medical University of Graz and Joanneum Research in Austria to assess AT247’s pharmacokinetic and pharmacodynamic profiles in Type 1 diabetes patients.

Arecor CEO Sarah Howell said: “In addition to the potential to improve blood glucose control after meals, AT247 may play a critical role in advancing artificial pancreas systems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape. We look forward to reporting the full data from this Phase I study in due course.”

The company submitted a clinical trial application for the Phase I study in January this year and secured regulatory approval from the Austrian Federal Office for Safety in Health Care in March.

Patient dosing was commenced in May and concluded in October along with all patient visits.

Following the completion of the Phase I trial, the company intends to further study the ultra-rapid acting insulin product in the clinical setting next year under its accelerated development pathway.

Arecor is also developing an ultra-concentrated rapid-acting insulin product to help treat diabetes.